Germline genetic testing after cancer diagnosis in California and Georgia

Germline genetic testing is recommended for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalizes cancer screening and prevention. An observational study that included 1,369,602 patients diagnosed with cancer between 2013 and 2019 in California and Georgia, found that the prevalence of germline genetic testing was low (6.8%). Prevalence of testing was highest in males with breast cancer (50%) and in patients with ovarian cancer (38.6%). The authors conclude that few patients diagnosed with cancer underwent germline testing.